Fiona Thistlethwaite

Involvement of Brca2 in DNA Repair

Ketan J. Patel, Veronica Yu, Hyun‐Sook Lee et al. · Molecular Cell · 1998 · 629 citations · Full text

Chromatin, Genome Instability, Dna Damage +4

Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study

Udai Banerji, Carla M.L. van Herpen, Cristina Saura et al. · The Lancet Oncology · 2019 · 549 citations · Full text

Breast Oncology, Her2-expressing Breast Cancer, Medicine +9

The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity

Fiona Thistlethwaite, David E. Gilham, Ryan D. Guest et al. · Cancer Immunology Immunotherapy · 2017 · 395 citations · Full text

Utility of ctDNA to support patient selection for early phase clinical trials: the TARGET study

Dominic G. Rothwell, Mahmood Ayub, Natalie Cook et al. · Nature Medicine · 2019 · 302 citations

Genetic Testing, Oncology, Cancer Detection +11

Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial

Toni K. Choueiri, James Larkin, Mototsugu Oya et al. · The Lancet Oncology · 2018 · 257 citations

Phase 1B, Urology, Oncology +7